배너이미지

Technology

Intraseptal RF ablation

Hypertrophic Obstructive Cardiomyopathy


Hypertrophic cardiomyopathy is a disease known to occur at a rate of 1 in 500 people, and is a disease that causes abnormal thickening of the myocardium, which causes the heart to deform and fail to function normally.

In about 10% of patients with hypertrophic cardiomyopathy, the left ventricular outflow tract narrows due to pathological hypertrophy of the myocardium, which puts a load on blood flow from the left ventricle to the aorta, causing more symptoms of heart function. This case is specifically called hypertrophic obstructive cardiomyopathy (HOCM).

The standard treatment method for hypertrophic cardiomyopathy is surgical treatment, and in the case of HOCM, the symptoms are severe enough to the extent that the patient's daily life is difficult, so treatment to resolve the symptoms is required. The current standard treatment is to resect the thickened myocardium through thoracotomy (myocardial resection, septal myectomy).

This treatment is accompanied by open thoracic and high complications, so in many cases, patients are not well treated.

심근절제술의 개요와 개흉수술을 통한 심근 절제

[Overview of myocardial resection (top) and
myocardial resection through thoracotomy (bottom)]

Various trials for non-invasive treatment of hypertrophic cardiomyopathy and ventricular septal radiofrequency cauterization treatment technology

Intraseptal RF ablation


Recently, in China, a method of RF ablation in which the myocardium is resected using a radiofrequency electrode through a needle penetrating the heart into a thickened myocardium was introduced for the first time in the world. The results of the study are incredibly good, and the article was published in JACC, the most authoritative journal in the field of cardiology in 2018.

Although this method is a minimally invasive method, it is attracting the attention of academia for its excellent therapeutic effect that was not expected in septal alcohol ablation. Still, the dangerous approach of having to penetrate the heart from the chest wall through a thick needle remains a problem to be solved.

As an alternative to such surgical treatment, we are developing a catheter-based ventricular septal RF ablation catheter technology, which can be applied to HOCM patients as a safer and more convenient procedure.

There are 36,000 new cases of HOCM annually,
and catheter-based treatment is estimated to have a market of $400 million (KRW 500 billion) annually, targeting 20% of these patients.

In addition, with the expansion of the intravascular RF ablation catheter, it is estimated to have a market size of $500 million (KRW 600 billion) per year for preemptive ablation before TMVR treatment (mitral valve replacement), and $60 million (KRW 70 billion) per year for intramyocardial ablation for ventricular tachycardia treatment.